Want to see JP:4263 full AI Analyst Report?
4263 Stock Chart & Stats
¥821.00
¥24.00(3.84%)
At close: 4:00 PM EST
¥821.00
¥24.00(3.84%)
Day’s Range― - ―
52-Week Range¥558.00 - ¥1,231.00
Previous CloseN/A
Volume269.90K
Average Volume (3M)121.17K
Market Cap
¥9.41B
Enterprise Value¥12.28K
Total Cash (Recent Filing)¥3.96B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-28.81
Shares Outstanding16,868,100
10 Day Avg. Volume117,240
30 Day Avg. Volume121,170
Financial Highlights & Ratios
PEG Ratio-1.37
Price to Book (P/B)3.59
Price to Sales (P/S)29.38
P/FCF Ratio-26.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)46.6
Revenue Forecast (FY)¥2.20B
Bulls Say, Bears Say
Bulls Say
Very High Gross MarginsSustaining ~96–98% gross margins indicates a high-value, capital-light service or software-driven model with strong pricing power. That margin profile supports durable profitability potential as revenue scales and provides room for operating leverage if fixed costs are controlled.
Strong Revenue AccelerationAn ~81% year-over-year top-line increase signals accelerating commercial traction and product-market fit. Durable revenue momentum over multiple quarters can underpin future operating leverage, expand addressable market share, and validate long-term demand for the company’s digital healthcare offerings.
Conservative, Debt-free Balance SheetZero debt and meaningful equity (about ¥4.07B in 2026) materially lower financial risk and preserve strategic flexibility. This capital structure supports continued investment in growth or weathering cash burn without immediate solvency pressure, improving resilience while profit metrics are addressed.
Bears Say
Sustained Negative Cash FlowPersistent negative operating and free cash flow shows current revenue does not cover operating costs, creating ongoing cash burn. Over 2-6 months this reduces runway, raises the probability of equity or financing raises, and constrains the company’s ability to invest without diluting shareholders or increasing leverage.
Large Operating And Net LossesDeep operating and net losses despite strong gross margins indicate high fixed or scaling costs and inability to achieve operating leverage. This structural unprofitability risks further equity erosion and means management must materially reduce costs or substantially grow revenue to reach sustainable profitability.
Declining Equity BaseShrinking shareholders' equity reflects cumulative losses eroding the balance sheet cushion. Over time this narrows flexibility for investment, increases vulnerability to future shocks, and may force dilutive capital raises or limit strategic options if profitability does not improve.
4263 FAQ
What was SUSMED,Inc.’s price range in the past 12 months?
SUSMED,Inc. lowest stock price was ¥558.00 and its highest was ¥1231.00 in the past 12 months.
What is SUSMED,Inc.’s market cap?
SUSMED,Inc.’s market cap is ¥9.41B.
When is SUSMED,Inc.’s upcoming earnings report date?
SUSMED,Inc.’s upcoming earnings report date is Nov 06, 2026 which is in 86 days.
How were SUSMED,Inc.’s earnings last quarter?
SUSMED,Inc. released its earnings results on Aug 07, 2026. The company reported -¥2.97 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is SUSMED,Inc. overvalued?
According to Wall Street analysts SUSMED,Inc.’s price is currently Overvalued.
Does SUSMED,Inc. pay dividends?
SUSMED,Inc. does not currently pay dividends.
What is SUSMED,Inc.’s EPS estimate?
SUSMED,Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SUSMED,Inc. have?
SUSMED,Inc. has 16,868,100 shares outstanding.
What happened to SUSMED,Inc.’s price movement after its last earnings report?
SUSMED,Inc. reported an EPS of -¥2.97 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.999%.
Which hedge fund is a major shareholder of SUSMED,Inc.?
Currently, no hedge funds are holding shares in JP:4263
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SUSMED,Inc.
SUSMED,Inc. develops and sells therapeutic applications in Japan. It operates through DTx product business, and DTx platform business segments. The company develops smartphone based digital therapeutics applications for diseases with insomnia, breast cancer, and kidney disease. It also develops and sells development platform for therapeutic apps and clinical trial systems. In addition, the company offers medical data analysis and consulting services. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.